Publications Flatmark Group

Publications published since 1999 from OUS - Translational Cancer Therapy (Flatmark)

343 publications found

Publications 2024

1. Angulo JC, Larrinaga G, Lecumberri D, Iturregui AM, Solano-Iturri JD, Lawrie CH, Armesto M, Dorado JF, Nunes-Xavier CE, Pulido R, Manini C, López JI (2024)
   Predicting Survival of Metastatic Clear Cell Renal Cell Cancer Treated with VEGFR-TKI-Based Sequential Therapy
   Cancers (Basel), 16 (16)
   DOI 10.3390/cancers16162786, PubMed 39199559
2. Dagenborg VJ, Brudvik KW, Lund-Andersen C, Torgunrud A, Lund-Iversen M, Flatmark K, Larsen SG, Yaqub S (2024)
   Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy and Liver Resection is a Treatment Option for Patients With Peritoneal and Liver Metastases From Colorectal Cancer
   Ann Surg, 280 (5), 745-752
   DOI 10.1097/SLA.0000000000006492, PubMed 39185557
3. Davidson B, Holth A, Lindemann K, Zahl Eriksson AG, Nilsen TA, Torgunrud A (2024)
   Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
   Virchows Arch (in press)
   DOI 10.1007/s00428-024-03821-9, PubMed 38733380
4. Emaldi M, Alamillo-Maeso P, Rey-Iborra E, Mosteiro L, Lecumberri D, Pulido R, López JI, Nunes-Xavier CE (2024)
   A functional role for glycosylated B7-H5/VISTA immune checkpoint protein in metastatic clear cell renal cell carcinoma
   iScience, 27 (9), 110587
   DOI 10.1016/j.isci.2024.110587, PubMed 39262813
5. Foote JB, Mattox TE, Keeton AB, Chen X, Smith F, Berry KL, Holmes T, Wang J, Huang CH, Ward AB, Mitra AK, Ramirez-Alcantara V, Hardy C, Fleten KG, Flatmark K, Yoon KJ, Sarvesh S, Nagaraju GP, Bandi DSR, Maxuitenko YY, Valiyaveettil J, Carstens JL, Buchsbaum DJ, Yang J, Zhou G et al. (2024)
   A Novel Pan-RAS Inhibitor with a Unique Mechanism of Action Blocks Tumor Growth in Mouse Models of GI Cancer
   bioRxiv
   DOI 10.1101/2023.05.17.541233, PubMed 38328254
6. Lund-Andersen C, Torgunrud A, Kanduri C, Dagenborg VJ, Frøysnes IS, Larsen MM, Davidson B, Larsen SG, Flatmark K (2024)
   Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer
   J Transl Med, 22 (1), 646
   DOI 10.1186/s12967-024-05467-2, PubMed 38982444
7. Nunes-Xavier CE (2024)
   Editorial: Co-inhibitory immune checkpoint proteins as biomarkers and therapeutic targets in cancer
   Transl Oncol, 47, 102005
   DOI 10.1016/j.tranon.2024.102005, PubMed 39034056
8. Patrick-Brown TDJH, Barratt-Due A, Trøseid M, Dyrhol-Riise AM, Nezvalova-Henriksen K, Kåsine T, Aukrust P, Olsen IC, NOR Solidarity consortium (2024)
   The effects of remdesivir on long-term symptoms in patients hospitalised for COVID-19: a pre-specified exploratory analysis
   Commun Med (Lond), 4 (1), 231
   DOI 10.1038/s43856-024-00650-4, PubMed 39533001
9. Patrick-Brown TDJH, Bourner J, Kali S, Trøseid M, Yazdanpanah Y, Olliaro P, Olsen IC (2024)
   Experiences and challenges with the new European Clinical Trials Regulation
   Trials, 25 (1), 3
   DOI 10.1186/s13063-023-07869-x, PubMed 38167484
10. Pulido R, López JI, Nunes-Xavier CE (2024)
    B7-H3: a robust target for immunotherapy in prostate cancer
    Trends Cancer, 10 (7), 584-587
    DOI 10.1016/j.trecan.2024.05.003, PubMed 38839545
11. Ree AH, Høye E, Esbensen Y, Beitnes AR, Negård A, Bernklev L, Tetlie LK, Fretland ÅA, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Nilsen HL, Flatmark K, Meltzer S (2024)
    Complete response of metastatic microsatellite-stable BRAF V600E colorectal cancer to first-line oxaliplatin-based chemotherapy and immune checkpoint blockade
    Oncoimmunology, 13 (1), 2372886
    DOI 10.1080/2162402X.2024.2372886, PubMed 38952672
12. Ree AH, Šaltytė Benth J, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Johansen C, Negård A, Bjørnetrø T, Nilsen HL, Berg JP, Flatmark K, Meltzer S (2024)
    First-line oxaliplatin-based chemotherapy and nivolumab for metastatic microsatellite-stable colorectal cancer-the randomised METIMMOX trial
    Br J Cancer, 130 (12), 1921-1928
    DOI 10.1038/s41416-024-02696-6, PubMed 38664577
13. Torices L, Nunes-Xavier CE, Mingo J, Luna S, Erramuzpe A, Cortés JM, Pulido R (2024)
    Induction of Translational Readthrough on Protein Tyrosine Phosphatases Targeted by Premature Termination Codon Mutations in Human Disease
    Methods Mol Biol, 2743, 1-19
    DOI 10.1007/978-1-0716-3569-8_1, PubMed 38147205
14. Torices L, Nunes-Xavier CE, Pulido R (2024)
    Potentiation by Protein Synthesis Inducers of Translational Readthrough of Pathogenic Premature Termination Codons in PTEN Isoforms
    Cancers (Basel), 16 (16)
    DOI 10.3390/cancers16162836, PubMed 39199607

Publications 2023

1. Arjona-Sanchez A, Martinez-López A, Moreno-Montilla MT, Mulsow J, Lozano-Lominchar P, Martínez-Torres B, Rau B, Canbay E, Sommariva A, Milione M, Deraco M, Sgarbura O, Torgunrud A, Kepenekian V, Carr NJ, Hoorens A, Delhorme JB, Wernert R, Goere D, Martin-Roman L, Cosyns S, Flatmark K, Davidson B, Khellaf L, Pereira-Perez F et al. (2023)
   External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
   Eur J Surg Oncol, 49 (8), 1481-1488
   DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
2. Doutel D, Davidson B, Nitschke Pettersen IK, Torgunrud A (2023)
   Molecular characteristics of low-grade serous carcinoma in effusions
   Cytopathology, 34 (2), 99-105
   DOI 10.1111/cyt.13207, PubMed 36609991
3. Getu AA, Tigabu A, Zhou M, Lu J, Fodstad Ø, Tan M (2023)
   New frontiers in immune checkpoint B7-H3 (CD276) research and drug development
   Mol Cancer, 22 (1), 43
   DOI 10.1186/s12943-023-01751-9, PubMed 36859240
4. Hyldbakk A, Fleten KG, Snipstad S, Åslund AKO, Davies CL, Flatmark K, Mørch Y (2023)
   Intraperitoneal administration of cabazitaxel-loaded nanoparticles in peritoneal metastasis models
   Nanomedicine, 48, 102656
   DOI 10.1016/j.nano.2023.102656, PubMed 36646195
5. Ito I, Yousef AM, Dickson PN, Naini ZA, White MG, Fleten KG, Flatmark K, Fournier KF, Fowlkes NW, Shen JP (2023)
   Antitumor activity of intraperitoneal paclitaxel in orthotopic patient-derived xenograft models of mucinous appendiceal adenocarcinoma
   bioRxiv
   DOI 10.1101/2023.02.01.526672, PubMed 36993681
6. López JI, Hogan MF, Sutton B, Church SE, Angulo JC, Nunes-Xavier CE (2023)
   Distinct spatial landscapes in clear-cell renal cell carcinoma as revealed by whole transcriptome analysis
   Immunooncol Technol, 21, 100690
   DOI 10.1016/j.iotech.2023.100690, PubMed 38292905
7. Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
   The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
   Sci Rep, 13 (1), 7339
   DOI 10.1038/s41598-023-34087-x, PubMed 37147361
8. Nunes-Xavier CE, Emaldi M, Mingo J, Øyjord T, Mælandsmo GM, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López JI, Pulido R (2023)
   Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
   Sci Rep, 13 (1), 9186
   DOI 10.1038/s41598-023-36328-5, PubMed 37280349
9. Nygaard V, Ree AH, Dagenborg VJ, Børresen-Dale AL, Edwin B, Fretland ÅA, Grzyb K, Haugen MH, Mælandsmo GM, Flatmark K (2023)
   A PRRX1 Signature Identifies TIM-3 and VISTA as Potential Immune Checkpoint Targets in a Subgroup of Microsatellite Stable Colorectal Cancer Liver Metastases
   Cancer Res Commun, 3 (2), 235-244
   DOI 10.1158/2767-9764.CRC-22-0295, PubMed 36968142
10. Patrick-Brown TDJH, Mohamed F, Thrower A, Torgunrud A, Cosyns S, Canbay E, Villeneuve L, Flatmark K, Brandl A (2023)
    Determining a minimum data set for reporting clinical and radiologic data for pseudomyxoma peritonei
    Pleura Peritoneum, 8 (1), 1-9
    DOI 10.1515/pp-2022-0200, PubMed 37020469
11. Pulido R, Nunes-Xavier CE (2023)
    Editorial: Cell and Developmental Signalling in Neuroblastoma
    Front Cell Dev Biol, 10, 1126352
    DOI 10.3389/fcell.2022.1126352, PubMed 36684434
12. Solbakken AM, Flatmark K (2023)
    ASO Author Reflections: Navigation-Assisted Surgery for Locally Advanced and Recurrent Rectal Cancer: The NAVI-LARRC Trial
    Ann Surg Oncol, 30 (12), 7633-7634
    DOI 10.1245/s10434-023-14058-2, PubMed 37573284
13. Solbakken AM, Sellevold S, Spasojevic M, Julsrud L, Emblemsvåg HL, Reims HM, Sørensen O, Thorgersen EB, Fauske L, Ågren JSM, Brennhovd B, Ryder T, Larsen SG, Flatmark K (2023)
    Navigation-Assisted Surgery for Locally Advanced Primary and Recurrent Rectal Cancer
    Ann Surg Oncol, 30 (12), 7602-7611
    DOI 10.1245/s10434-023-13964-9, PubMed 37481493
14. Thorgersen EB, Solbakken AM, Strøm TK, Goscinski M, Spasojevic M, Larsen SG, Flatmark K (2023)
    Short-term results after robot-assisted surgery for primary rectal cancers requiring beyond total mesorectal excision in multiple compartments
    Scand J Surg, 113 (1), 3-12
    DOI 10.1177/14574969231200654, PubMed 37787437
15. Torices L, Nunes-Xavier CE, López JI, Pulido R (2023)
    Novel anti-PTEN C2 domain monoclonal antibodies to analyse the expression and function of PTEN isoform variants
    PLoS One, 18 (8), e0289369
    DOI 10.1371/journal.pone.0289369, PubMed 37527256

Publications 2022

1. Alaña L, Nunes-Xavier CE, Zaldumbide L, Martin-Guerrero I, Mosteiro L, Alba-Pavón P, Villate O, García-Obregón S, González-García H, Herraiz R, Astigarraga I, Pulido R, García-Ariza M (2022)
   Identification and Functional Analysis of a Novel CTNNB1 Mutation in Pediatric Medulloblastoma
   Cancers (Basel), 14 (2)
   DOI 10.3390/cancers14020421, PubMed 35053583
2. Emaldi M, Nunes-Xavier CE (2022)
   B7-H4 Immune Checkpoint Protein Affects Viability and Targeted Therapy of Renal Cancer Cells
   Cells, 11 (9)
   DOI 10.3390/cells11091448, PubMed 35563753
3. Fleten KG, Hyldbakk A, Einen C, Benjakul S, Strand BL, Davies CL, Mørch Ý, Flatmark K (2022)
   Alginate Microsphere Encapsulation of Drug-Loaded Nanoparticles: A Novel Strategy for Intraperitoneal Drug Delivery
   Mar Drugs, 20 (12)
   DOI 10.3390/md20120744, PubMed 36547891
4. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2022)
   Corrigendum to "Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft", [Journal of Control Release, 293 (2019) 183-192]
   J Control Release, 349, 1
   DOI 10.1016/j.jconrel.2022.06.040, PubMed 35792388
5. Høye E, Dagenborg VJ, Torgunrud A, Lund-Andersen C, Fretland ÅA, Lorenz S, Edwin B, Hovig E, Fromm B, Inderberg EM, Greiff V, Ree AH, Flatmark K (2022)
   T cell receptor repertoire sequencing reveals chemotherapy-driven clonal expansion in colorectal liver metastases
   Gigascience, 12
   DOI 10.1093/gigascience/giad032, PubMed 37161965
6. Høye E, Fromm B, Böttger PHM, Domanska D, Torgunrud A, Lund-Andersen C, Abrahamsen TW, Fretland ÅA, Dagenborg VJ, Lorenz S, Edwin B, Hovig E, Flatmark K (2022)
   A comprehensive framework for analysis of microRNA sequencing data in metastatic colorectal cancer
   NAR Cancer, 4 (1), zcab051
   DOI 10.1093/narcan/zcab051, PubMed 35047825
7. Meltzer S, Negård A, Bakke KM, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Flatmark K, Ree AH (2022)
   Early radiologic signal of responsiveness to immune checkpoint blockade in microsatellite-stable/mismatch repair-proficient metastatic colorectal cancer
   Br J Cancer, 127 (12), 2227-2233
   DOI 10.1038/s41416-022-02004-0, PubMed 36229579
8. Nunes-Xavier CE, Emaldi M, Guldvik IJ, Ramberg H, Taskén KA, Mælandsmo GM, Fodstad Ø, Llarena R, Pulido R, López JI (2022)
   Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer
   Pathol Res Pract, 241, 154243
   DOI 10.1016/j.prp.2022.154243, PubMed 36481650
9. Nunes-Xavier CE, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo GM, Fodstad Ø, Llarena R, López JI, Pulido R (2022)
   Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
   Front Oncol, 12, 873516
   DOI 10.3389/fonc.2022.873516, PubMed 35692804
10. Nyakas M, Fleten KG, Haugen MH, Engedal N, Sveen C, Farstad IN, Flørenes VA, Prasmickaite L, Mælandsmo GM, Seip K (2022)
    AXL inhibition improves BRAF-targeted treatment in melanoma
    Sci Rep, 12 (1), 5076
    DOI 10.1038/s41598-022-09078-z, PubMed 35332208
11. Pulido R, Nunes-Xavier CE (2022)
    Hopes on immunotherapy targeting B7-H3 in neuroblastoma
    Transl Oncol, 27, 101580
    DOI 10.1016/j.tranon.2022.101580, PubMed 36327699
12. Ree AH, Mælandsmo GM, Flatmark K, Russnes HG, Gómez Castañeda M, Aas E (2022)
    Cost-effectiveness of molecularly matched off-label therapies for end-stage cancer - the MetAction precision medicine study
    Acta Oncol, 61 (8), 955-962
    DOI 10.1080/0284186X.2022.2098053, PubMed 35943168
13. Torices L, Mingo J, Rodríguez-Escudero I, Fernández-Acero T, Luna S, Nunes-Xavier CE, López JI, Mercadillo F, Currás M, Urioste M, Molina M, Cid VJ, Pulido R (2022)
    Functional analysis of PTEN variants of unknown significance from PHTS patients unveils complex patterns of PTEN biological activity in disease
    Eur J Hum Genet, 31 (5), 568-577
    DOI 10.1038/s41431-022-01265-w, PubMed 36543932

Publications 2021

1. Andersson Y, Fleten KG, Abrahamsen TW, Reed W, Davidson B, Flatmark K (2021)
   Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
   Cancers (Basel), 13 (11)
   DOI 10.3390/cancers13112819, PubMed 34198773
2. Dagenborg VJ, Marshall SE, Grzyb K, Fretland ÅA, Lund-Iversen M, Mælandsmo GM, Ree AH, Edwin B, Yaqub S, Flatmark K (2021)
   Low Concordance Between T-Cell Densities in Matched Primary Tumors and Liver Metastases in Microsatellite Stable Colorectal Cancer
   Front Oncol, 11, 671629
   DOI 10.3389/fonc.2021.671629, PubMed 34178659
3. Flatmark K, Torgunrud A, Fleten KG, Davidson B, Juul HV, Mensali N, Lund-Andersen C, Inderberg EM (2021)
   Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
   J Immunother Cancer, 9 (10)
   DOI 10.1136/jitc-2021-003109, PubMed 34711663
4. Fleten KG, Eksteen JJ, Mauseth B, Camilio KA, Vasskog T, Sveinbjørnsson B, Rekdal Ø, Mælandsmo GM, Flatmark K (2021)
   Oncolytic peptides DTT-205 and DTT-304 induce complete regression and protective immune response in experimental murine colorectal cancer
   Sci Rep, 11 (1), 6731
   DOI 10.1038/s41598-021-86239-6, PubMed 33762676
5. Larrinaga G, Calvete-Candenas J, Solano-Iturri JD, Martín AM, Pueyo A, Nunes-Xavier CE, Pulido R, Dorado JF, López JI, Angulo JC (2021)
   (Pro)renin Receptor Is a Novel Independent Prognostic Marker in Invasive Urothelial Carcinoma of the Bladder
   Cancers (Basel), 13 (22)
   DOI 10.3390/cancers13225642, PubMed 34830803
6. Larsen SG, Goscinski MA, Dueland S, Steigen SE, Hofsli E, Torgunrud A, Lund-Iversen M, Dagenborg VJ, Flatmark K, Sorbye H (2021)
   Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients
   Br J Cancer, 126 (5), 726-735
   DOI 10.1038/s41416-021-01620-6, PubMed 34887523
7. Luna S, Torices L, Mingo J, Amo L, Rodríguez-Escudero I, Ruiz-Ibarlucea P, Erramuzpe A, Cortés JM, Tejada MI, Molina M, Nunes-Xavier CE, López JI, Cid VJ, Pulido R (2021)
   A global analysis of the reconstitution of PTEN function by translational readthrough of PTEN pathogenic premature termination codons
   Hum Mutat, 42 (5), 551-566
   DOI 10.1002/humu.24186, PubMed 33600059
8. Lund-Andersen C, Torgunrud A, Fleten KG, Flatmark K (2021)
   Omics analyses in peritoneal metastasis-utility in the management of peritoneal metastases from colorectal cancer and pseudomyxoma peritonei: a narrative review
   J Gastrointest Oncol, 12 (Suppl 1), S191-S203
   DOI 10.21037/jgo-20-136, PubMed 33968437
9. Mariathasan AB, Boye K, Dueland S, Flatmark K, Larsen SG (2021)
   Metastases in locally advanced rectal cancer undergoing curatively intended treatment
   Eur J Surg Oncol, 47 (9), 2377-2383
   DOI 10.1016/j.ejso.2021.04.023, PubMed 34049768
10. Meltzer S, Torgunrud A, Abrahamsson H, Solbakken AM, Flatmark K, Dueland S, Bakke KM, Bousquet PA, Negård A, Johansen C, Lyckander LG, Larsen FO, Schou JV, Redalen KR, Ree AH (2021)
    The circulating soluble form of the CD40 costimulatory immune checkpoint receptor and liver metastasis risk in rectal cancer
    Br J Cancer, 125 (2), 240-246
    DOI 10.1038/s41416-021-01377-y, PubMed 33837301
11. Nunes-Xavier CE, Kildal W, Kleppe A, Danielsen HE, Waehre H, Llarena R, Maelandsmo GM, Fodstad Ø, Pulido R, López JI (2021)
    Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer
    Prostate, 81 (12), 838-848
    DOI 10.1002/pros.24180, PubMed 34125445
12. Nunes-Xavier CE, Zaldumbide L, Mosteiro L, López-Almaraz R, García de Andoin N, Aguirre P, Emaldi M, Torices L, López JI, Pulido R (2021)
    Protein Tyrosine Phosphatases in Neuroblastoma: Emerging Roles as Biomarkers and Therapeutic Targets
    Front Cell Dev Biol, 9, 811297
    DOI 10.3389/fcell.2021.811297, PubMed 34957126
13. Pavlović M, Scheffer L, Motwani K, Kanduri C, Kompova R, Vazov N, Waagan K, Bernal FLM, Costa AA, Corrie B, Akbar R, Al Hajj GS, Balaban G, Brusko TM, Chernigovskaya M, Christley S, Cowell LG, Frank R, Grytten I, Gundersen S, Haff IH, Hovig E, Hsieh PH, Klambauer G, Kuijjer ML et al. (2021)
    The immuneML ecosystem for machine learning analysis of adaptive immune receptor repertoires
    Nat Mach Intell, 3 (11), 936-944
    DOI 10.1038/s42256-021-00413-z, PubMed 37396030
14. Svendsen HA, Meling TR, Nygaard V, Waagene S, Russnes H, Juell S, Rogne SG, Pahnke J, Helseth E, Fodstad Ø, Maelandsmo GM (2021)
    Novel human melanoma brain metastasis models in athymic nude fox1^nu mice: Site-specific metastasis patterns reflecting their clinical origin
    Cancer Med, 10 (23), 8604-8613
    DOI 10.1002/cam4.4334, PubMed 34612023
15. Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2021)
    Correction to: Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of highgrade pseudomyxoma peritonei
    Clin Exp Metastasis, 38 (2), 253
    DOI 10.1007/s10585-021-10084-0, PubMed 33649933
16. Thorgersen EB, Asvall J, Frøysnes IS, Schjalm C, Larsen SG, Dueland S, Andersson Y, Fodstad Ø, Mollnes TE, Flatmark K (2021)
    Increased Local Inflammatory Response to MOC31PE Immunotoxin After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
    Ann Surg Oncol, 28 (9), 5252-5262
    DOI 10.1245/s10434-021-10022-0, PubMed 34019185
17. Thorgersen EB, Flatmark K (2021)
    ASO Author Reflections: The Peritoneum is an Active Immunological Compartment
    Ann Surg Oncol, 28 (9), 5263-5264
    DOI 10.1245/s10434-021-10036-8, PubMed 33939046
18. Torices L, de Las Heras J, Arango-Lasprilla JC, Cortés JM, Nunes-Xavier CE, Pulido R (2021)
    MMADHC premature termination codons in the pathogenesis of cobalamin D disorder: Potential of translational readthrough reconstitution
    Mol Genet Metab Rep, 26, 100710
    DOI 10.1016/j.ymgmr.2021.100710, PubMed 33552904

Publications 2020

1. Aghayan DL, Kazaryan AM, Dagenborg VJ, Røsok BI, Fagerland MW, Waaler Bjørnelv GM, Kristiansen R, Flatmark K, Fretland ÅA, Edwin B, OSLO-COMET Survival Study Collaborators (2020)
   Long-Term Oncologic Outcomes After Laparoscopic Versus Open Resection for Colorectal Liver Metastases : A Randomized Trial
   Ann Intern Med, 174 (2), 175-182
   DOI 10.7326/M20-4011, PubMed 33197213
2. Dagenborg VJ, Marshall SE, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, Høye E, Berstad AE, Fretland ÅA, Edwin B, Ree AH, Flatmark K (2020)
   Neoadjuvant chemotherapy is associated with a transient increase of intratumoral T-cell density in microsatellite stable colorectal liver metastases
   Cancer Biol Ther, 21 (5), 432-440
   DOI 10.1080/15384047.2020.1721252, PubMed 32098573
3. Flatmark K, Mohamed F (2020)
   ASO Author Reflections: Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
   Ann Surg Oncol, 27 (Suppl 3), 771-772
   DOI 10.1245/s10434-020-08691-4, PubMed 32495284
4. Flem-Karlsen K, Fodstad Ø, Nunes-Xavier CE (2020)
   B7-H3 Immune Checkpoint Protein in Human Cancer
   Curr Med Chem, 27 (24), 4062-4086
   DOI 10.2174/0929867326666190517115515, PubMed 31099317
5. Fleten KG, Lund-Andersen C, Waagene S, Abrahamsen TW, Mørch Y, Boye K, Torgunrud A, Flatmark K (2020)
   Experimental Treatment of Mucinous Peritoneal Metastases Using Patient-Derived Xenograft Models
   Transl Oncol, 13 (8), 100793
   DOI 10.1016/j.tranon.2020.100793, PubMed 32447231
6. Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
   MirGeneDB 2.0: the metazoan microRNA complement
   Nucleic Acids Res, 48 (D1), D132-D141
   DOI 10.1093/nar/gkz885, PubMed 31598695
7. Fromm B, Domanska D, Høye E, Ovchinnikov V, Kang W, Aparicio-Puerta E, Johansen M, Flatmark K, Mathelier A, Hovig E, Hackenberg M, Friedländer MR, Peterson KJ (2020)
   MirGeneDB 2.0: the metazoan microRNA complement
   Nucleic Acids Res, 48 (D1), D1172
   DOI 10.1093/nar/gkz1016, PubMed 31642479
8. Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2020)
   Corrigendum to "Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer" [Transl Oncol 12 (8) (2019) 1038-1044]
   Transl Oncol, 13 (1), 122-124
   DOI 10.1016/j.tranon.2019.09.005, PubMed 31843135
9. Patrick-Brown TDJH, Carr NJ, Swanson DM, Larsen S, Mohamed F, Flatmark K (2020)
   Estimating the Prevalence of Pseudomyxoma Peritonei in Europe Using a Novel Statistical Method
   Ann Surg Oncol, 28 (1), 252-257
   DOI 10.1245/s10434-020-08655-8, PubMed 32488520
10. Ree AH, Nygaard V, Boye K, Heinrich D, Dueland S, Bergheim IR, Johansen C, Beiske K, Negård A, Lund-Iversen M, Nygaard V, Hovig E, Nakken S, Nasser S, Julsrud L, Reisse CH, Ruud EA, Kristensen VN, Flørenes VA, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Russnes HG, Mælandsmo GM, Flatmark K (2020)
    Molecularly matched therapy in the context of sensitivity, resistance, and safety; patient outcomes in end-stage cancer - the MetAction study
    Acta Oncol, 59 (7), 733-740
    DOI 10.1080/0284186X.2020.1742377, PubMed 32208873
11. Saeednejad Zanjani L, Madjd Z, Axcrona U, Abolhasani M, Rasti A, Asgari M, Fodstad Ø, Andersson Y (2020)
    Cytoplasmic expression of B7-H3 and membranous EpCAM expression are associated with higher grade and survival outcomes in patients with clear cell renal cell carcinoma
    Ann Diagn Pathol, 46, 151483
    DOI 10.1016/j.anndiagpath.2020.151483, PubMed 32143173

Publications 2019

1. Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH (2019)
   High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer
   BMC Cancer, 19 (1), 488
   DOI 10.1186/s12885-019-5724-z, PubMed 31122213
2. Aghayan DL, Fretland ÅA, Kazaryan AM, Sahakyan MA, Dagenborg VJ, Bjørnbeth BA, Flatmark K, Kristiansen R, Edwin B (2019)
   Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial
   HPB (Oxford), 21 (11), 1485-1490
   DOI 10.1016/j.hpb.2019.03.358, PubMed 30962136
3. Andersson Y, Inderberg EM, Kvalheim G, Herud TM, Engebraaten O, Flatmark K, Dueland S, Fodstad Ø (2019)
   Immune stimulatory effect of anti-EpCAM immunotoxin - improved overall survival of metastatic colorectal cancer patients
   Acta Oncol, 59 (4), 404-409
   DOI 10.1080/0284186X.2019.1704864, PubMed 31876430
4. Bains SJ, Abrahamsson H, Flatmark K, Dueland S, Hole KH, Seierstad T, Redalen KR, Meltzer S, Ree AH (2019)
   Immunogenic cell death by neoadjuvant oxaliplatin and radiation protects against metastatic failure in high-risk rectal cancer
   Cancer Immunol Immunother, 69 (3), 355-364
   DOI 10.1007/s00262-019-02458-x, PubMed 31893287
5. Brudvik KW, Jones RP, Giuliante F, Shindoh J, Passot G, Chung MH, Song J, Li L, Dagenborg VJ, Fretland ÅA, Røsok B, De Rose AM, Ardito F, Edwin B, Panettieri E, Larocca LM, Yamashita S, Conrad C, Aloia TA, Poston GJ, Bjørnbeth BA, Vauthey JN (2019)
   RAS Mutation Clinical Risk Score to Predict Survival After Resection of Colorectal Liver Metastases
   Ann Surg, 269 (1), 120-126
   DOI 10.1097/SLA.0000000000002319, PubMed 28549012
6. Calvete J, Larrinaga G, Errarte P, Martín AM, Dotor A, Esquinas C, Nunes-Xavier CE, Pulido R, López JI, Angulo JC (2019)
   The coexpression of fibroblast activation protein (FAP) and basal-type markers (CK 5/6 and CD44) predicts prognosis in high-grade invasive urothelial carcinoma of the bladder
   Hum Pathol, 91, 61-68
   DOI 10.1016/j.humpath.2019.07.002, PubMed 31279874
7. Flem-Karlsen K, Tekle C, Øyjord T, Flørenes VA, Mælandsmo GM, Fodstad Ø, Nunes-Xavier CE (2019)
   p38 MAPK activation through B7-H3-mediated DUSP10 repression promotes chemoresistance
   Sci Rep, 9 (1), 5839
   DOI 10.1038/s41598-019-42303-w, PubMed 30967582
8. Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM (2019)
   A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases
   Transl Oncol, 12 (7), 951-958
   DOI 10.1016/j.tranon.2019.04.001, PubMed 31096111
9. Fretland ÅA, Dagenborg VJ, Waaler Bjørnelv GM, Aghayan DL, Kazaryan AM, Barkhatov L, Kristiansen R, Fagerland MW, Edwin B, Andersen MH (2019)
   Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases
   Br J Surg, 106 (10), 1372-1380
   DOI 10.1002/bjs.11227, PubMed 31322735
10. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2019)
    ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
    Eur J Surg Oncol, 47 (1), 134-138
    DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
11. Hausken J, Fretland ÅA, Edwin B, Andersen MH, Dagenborg VJ, Bjørnelv GMW, Kristiansen R, Røysland K, Kvarstein G, Tønnessen TI (2019)
    Intravenous Patient-controlled Analgesia Versus Thoracic Epidural Analgesia After Open Liver Surgery: A Prospective, Randomized, Controlled, Noninferiority Trial
    Ann Surg, 270 (2), 193-199
    DOI 10.1097/SLA.0000000000003209, PubMed 30676382
12. Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K (2019)
    Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
    Cold Spring Harb Mol Case Stud, 5 (2)
    DOI 10.1101/mcs.a003566, PubMed 30862609
13. Meltzer S, Bakke KM, Rød KL, Negård A, Flatmark K, Solbakken AM, Kristensen AT, Fuglestad AJ, Kersten C, Dueland S, Seierstad T, Hole KH, Lyckander LG, Larsen FO, Schou JV, Patrick Brown D, Abrahamsson H, Redalen KR, Ree AH (2019)
    Sex-related differences in primary metastatic site in rectal cancer; associated with hemodynamic factors?
    Clin Transl Radiat Oncol, 21, 5-10
    DOI 10.1016/j.ctro.2019.11.006, PubMed 31872084
14. Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR (2019)
    Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer
    Transl Oncol, 12 (8), 1038-1044
    DOI 10.1016/j.tranon.2019.04.014, PubMed 31146167
15. Mingo J, Luna S, Gaafar A, Nunes-Xavier CE, Torices L, Mosteiro L, Ruiz R, Guerra I, Llarena R, Angulo JC, López JI, Pulido R (2019)
    Precise definition of PTEN C-terminal epitopes and its implications in clinical oncology
    NPJ Precis Oncol, 3, 11
    DOI 10.1038/s41698-019-0083-4, PubMed 30993208
16. Nunes-Xavier CE, Angulo JC, Pulido R, López JI (2019)
    A Critical Insight into the Clinical Translation of PD-1/PD-L1 Blockade Therapy in Clear Cell Renal Cell Carcinoma
    Curr Urol Rep, 20 (1), 1
    DOI 10.1007/s11934-019-0866-8, PubMed 30645700
17. Nunes-Xavier CE, Aurtenetxe O, Zaldumbide L, López-Almaraz R, Erramuzpe A, Cortés JM, López JI, Pulido R (2019)
    Protein tyrosine phosphatase PTPN1 modulates cell growth and associates with poor outcome in human neuroblastoma
    Diagn Pathol, 14 (1), 134
    DOI 10.1186/s13000-019-0919-9, PubMed 31837707
18. Nunes-Xavier CE, Zaldumbide L, Aurtenetxe O, López-Almaraz R, López JI, Pulido R (2019)
    Dual-Specificity Phosphatases in Neuroblastoma Cell Growth and Differentiation
    Int J Mol Sci, 20 (5)
    DOI 10.3390/ijms20051170, PubMed 30866462
19. Pulido R, Mingo J, Gaafar A, Nunes-Xavier CE, Luna S, Torices L, Angulo JC, López JI (2019)
    Precise Immunodetection of PTEN Protein in Human Neoplasia
    Cold Spring Harb Perspect Med, 9 (12)
    DOI 10.1101/cshperspect.a036293, PubMed 31501265
20. Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM (2019)
    Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain
    Cancer Immunol Res, 7 (5), 701-706
    DOI 10.1158/2326-6066.CIR-18-0777, PubMed 30804006
21. Saeednejad Zanjani L, Madjd Z, Rasti A, Asgari M, Abolhasani M, Tam KJ, Roudi R, Mælandsmo GM, Fodstad Ø, Andersson Y (2019)
    Spheroid-Derived Cells From Renal Adenocarcinoma Have Low Telomerase Activity and High Stem-Like and Invasive Characteristics
    Front Oncol, 9, 1302
    DOI 10.3389/fonc.2019.01302, PubMed 31921617
22. Sørensen O, Andersen AM, Larsen SG, Giercksky KE, Flatmark K (2019)
    Intraperitoneal mitomycin C improves survival compared to cytoreductive surgery alone in an experimental model of high-grade pseudomyxoma peritonei
    Clin Exp Metastasis, 36 (6), 511-518
    DOI 10.1007/s10585-019-09991-0, PubMed 31541325

Publications 2018

1. Aurtenetxe O, Zaldumbide L, Erramuzpe A, López R, López JI, Cortés JM, Pulido R, Nunes-Xavier CE (2018)
   DUSP5 expression associates with poor prognosis in human neuroblastoma
   Exp Mol Pathol, 105 (3), 272-278
   DOI 10.1016/j.yexmp.2018.08.008, PubMed 30171833
2. Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH (2018)
   Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer
   Transl Oncol, 12 (1), 76-83
   DOI 10.1016/j.tranon.2018.09.010, PubMed 30273860
3. Flem-Karlsen K, Fodstad Ø, Tan M, Nunes-Xavier CE (2018)
   B7-H3 in Cancer - Beyond Immune Regulation
   Trends Cancer, 4 (6), 401-404
   DOI 10.1016/j.trecan.2018.03.010, PubMed 29860983
4. Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B (2018)
   Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial
   Ann Surg, 267 (2), 199-207
   DOI 10.1097/SLA.0000000000002353, PubMed 28657937
5. Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM (2018)
   Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft
   J Control Release, 293, 183-192
   DOI 10.1016/j.jconrel.2018.11.029, PubMed 30529259
6. Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH (2018)
   Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer
   Br J Cancer, 118 (10), 1322-1328
   DOI 10.1038/s41416-018-0085-y, PubMed 29695770
7. Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG (2018)
   Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement
   Eur J Surg Oncol, 44 (8), 1226-1232
   DOI 10.1016/j.ejso.2018.03.029, PubMed 29691115
8. Mikalsen SG, Mikalsen LTG, Sandvik JA, Aarnes EK, Fenne S, Flatmark K, Lyng H, Edin NFJ, Pettersen EO (2018)
   Low dose-rate irradiation with [³H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model
   Acta Oncol, 57 (9), 1216-1224
   DOI 10.1080/0284186X.2018.1457223, PubMed 29630428
9. Nunes-Xavier CE, Mingo J, López JI, Pulido R (2018)
   The role of protein tyrosine phosphatases in prostate cancer biology
   Biochim Biophys Acta Mol Cell Res, 1866 (1), 102-113
   DOI 10.1016/j.bbamcr.2018.06.016, PubMed 30401533
10. Saeednejad Zanjani L, Madjd Z, Abolhasani M, Rasti A, Shariftabrizi A, Mehrazma M, Fodstad Ø, Asgari M (2018)
    Human telomerase reverse transcriptase protein expression predicts tumour aggressiveness and survival in patients with clear cell renal cell carcinoma
    Pathology, 51 (1), 21-31
    DOI 10.1016/j.pathol.2018.08.019, PubMed 30466948
11. Spasojevic M, Mariathasan AB, Goscinski M, Thorgersen EB, Solbakken AM, Gullestad HP, Ryder T, Flatmark K, Larsen SG (2018)
    Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer
    Ann Surg Oncol, 25 (5), 1357-1365
    DOI 10.1245/s10434-018-6363-3, PubMed 29497909

Publications 2017

1. Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K (2017)
   MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
   Oncotarget, 8 (37), 61800-61809
   DOI 10.18632/oncotarget.18694, PubMed 28977905
2. Arstad C, Refinetti P, Kristensen AT, Giercksky KE, Ekstrøm PO (2017)
   Is detection of intraperitoneal exfoliated tumor cells after surgical resection of rectal cancer a prognostic factor of survival?
   BMC Cancer, 17 (1), 406
   DOI 10.1186/s12885-017-3365-7, PubMed 28592327
3. Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR (2017)
   Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival
   Acta Oncol, 56 (6), 813-818
   DOI 10.1080/0284186X.2017.1287951, PubMed 28464745
4. Domanska D, Vodák D, Lund-Andersen C, Salvatore S, Hovig E, Sandve GK (2017)
   The rainfall plot: its motivation, characteristics and pitfalls
   BMC Bioinformatics, 18 (1), 264
   DOI 10.1186/s12859-017-1679-8, PubMed 28521741
5. Eide N, Faye RS, Høifødt HK, Sandvik L, Qvale GA, Faber R, Jebsen P, Kvalheim G, Fodstad Ø (2017)
   The Results of Stricter Inclusion Criteria in an Immunomagnetic Detection Study of Micrometastatic Cells in Bone Marrow of Uveal Melanoma Patients - Relevance for Dormancy
   Pathol Oncol Res, 25 (1), 255-262
   DOI 10.1007/s12253-017-0355-7, PubMed 29098521
6. Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE (2017)
   Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells
   Pigment Cell Melanoma Res, 30 (5), 467-476
   DOI 10.1111/pcmr.12599, PubMed 28513992
7. Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K (2017)
   Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
   Ann Surg Oncol, 24 (7), 1916-1922
   DOI 10.1245/s10434-017-5814-6, PubMed 28224367
8. Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I (2017)
   Pathway-based classification of breast cancer subtypes
   Front Biosci (Landmark Ed), 22 (10), 1697-1712
   DOI 10.2741/4566, PubMed 28410140
9. Lim S, Phillips JB, Madeira da Silva L, Zhou M, Fodstad O, Owen LB, Tan M (2017)
   Interplay between Immune Checkpoint Proteins and Cellular Metabolism
   Cancer Res, 77 (6), 1245-1249
   DOI 10.1158/0008-5472.CAN-16-1647, PubMed 28246276
10. Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA et al. (2017)
    Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate
    ESMO Open, 2 (2), e000158
    DOI 10.1136/esmoopen-2017-000158, PubMed 28761742
11. Saeednejad Zanjani L, Madjd Z, Abolhasani M, Andersson Y, Rasti A, Shariftabrizi A, Asgari M (2017)
    Cytoplasmic expression of CD133 stemness marker is associated with tumor aggressiveness in clear cell renal cell carcinoma
    Exp Mol Pathol, 103 (2), 218-228
    DOI 10.1016/j.yexmp.2017.10.001, PubMed 29050853
12. Simovski B, Vodák D, Gundersen S, Domanska D, Azab A, Holden L, Holden M, Grytten I, Rand K, Drabløs F, Johansen M, Mora A, Lund-Andersen C, Fromm B, Eskeland R, Gabrielsen OS, Ferkingstad E, Nakken S, Bengtsen M, Nederbragt AJ, Thorarensen HS, Akse JA, Glad I, Hovig E, Sandve GK (2017)
    GSuite HyperBrowser: integrative analysis of dataset collections across the genome and epigenome
    Gigascience, 6 (7), 1-12
    DOI 10.1093/gigascience/gix032, PubMed 28459977
13. Wang MY, Nestvold J, Rekdal Ø, Kvalheim G, Fodstad Ø (2017)
    A novel rat fibrosarcoma cell line from transformed bone marrow-derived mesenchymal stem cells with maintained in vitro and in vivo stemness properties
    Exp Cell Res, 352 (2), 218-224
    DOI 10.1016/j.yexcr.2017.02.005, PubMed 28189639
14. Zanjani LS, Madjd Z, Abolhasani M, Rasti A, Fodstad O, Andersson Y, Asgari M (2017)
    Increased expression of CD44 is associated with more aggressive behavior in clear cell renal cell carcinoma
    Biomark Med, 12 (1), 45-61
    DOI 10.2217/bmm-2017-0142, PubMed 29243496
15. Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K (2017)
    Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases
    Oncotarget, 8 (44), 76290-76304
    DOI 10.18632/oncotarget.19350, PubMed 29100312
16. Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K (2017)
    Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide
    Oncotarget, 8 (44), 76921-76934
    DOI 10.18632/oncotarget.20217, PubMed 29100358

Publications 2016

1. Alonso A, Nunes-Xavier CE, Bayón Y, Pulido R (2016)
   The Extended Family of Protein Tyrosine Phosphatases
   Methods Mol Biol, 1447, 1-23
   DOI 10.1007/978-1-4939-3746-2_1, PubMed 27514797
2. Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K (2016)
   Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy
   Cancer Med, 5 (8), 1840-9
   DOI 10.1002/cam4.766, PubMed 27273130
3. Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K (2016)
   Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome
   Clin Oncol (R Coll Radiol), 28 (8), 532-9
   DOI 10.1016/j.clon.2016.01.014, PubMed 26888115
4. Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K (2016)
   Expression and clinical significance of Wee1 in colorectal cancer
   Tumour Biol, 37 (9), 12133-12140
   DOI 10.1007/s13277-016-5081-3, PubMed 27220319
5. Errarte P, Guarch R, Pulido R, Blanco L, Nunes-Xavier CE, Beitia M, Gil J, Angulo JC, López JI, Larrinaga G (2016)
   The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases
   PLoS One, 11 (12), e0169105
   DOI 10.1371/journal.pone.0169105, PubMed 28033421
6. Flatmark K, Høye E, Fromm B (2016)
   microRNAs as cancer biomarkers
   Scand J Clin Lab Invest Suppl, 245, S80-3
   DOI 10.1080/00365513.2016.1210330, PubMed 27542003
7. Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH (2016)
   Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?
   Radiother Oncol, 119 (3), 505-11
   DOI 10.1016/j.radonc.2016.02.020, PubMed 26968754
8. Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K (2016)
   Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases
   Clin Exp Metastasis, 34 (1), 51-62
   DOI 10.1007/s10585-016-9829-3, PubMed 27812769
9. Fleten KG, Flørenes VA, Prasmickaite L, Hill O, Sykora J, Mælandsmo GM, Engesæter B (2016)
   hvTRA, a novel TRAIL receptor agonist, induces apoptosis and sustained growth retardation in melanoma
   Cell Death Discov, 2, 16081
   DOI 10.1038/cddiscovery.2016.81, PubMed 28028438
10. Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K (2016)
    Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort
    J Surg Oncol, 114 (2), 222-7
    DOI 10.1002/jso.24290, PubMed 27173150
11. Hompland I, Bruland ØS, Ubhayasekhera K, Bergquist J, Boye K (2016)
    Clinical implications of repeated drug monitoring of imatinib in patients with metastatic gastrointestinal stromal tumour
    Clin Sarcoma Res, 6, 21
    DOI 10.1186/s13569-016-0062-2, PubMed 27999655
12. Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H (2016)
    Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
    Br J Cancer, 115 (8), 929-939
    DOI 10.1038/bjc.2016.278, PubMed 27599042
13. Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH (2016)
    Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening
    BMC Cancer, 16, 536
    DOI 10.1186/s12885-016-2601-x, PubMed 27461255
14. Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH (2016)
    Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy
    Cancer Res Treat, 49 (2), 374-386
    DOI 10.4143/crt.2016.080, PubMed 27488871
15. Kongsgaard A, Boye K, Fodstad Ø, Juell S, Jørgensen LH, Solberg S, Helland Å, Brustugun OT, Mælandsmo GM (2016)
    Detection of disseminated tumor cells in lymph nodes from patients with early stage non-small cell lung cancer
    Diagn Pathol, 11 (1), 50
    DOI 10.1186/s13000-016-0504-4, PubMed 27316334
16. Lim S, Liu H, Madeira da Silva L, Arora R, Liu Z, Phillips JB, Schmitt DC, Vu T, McClellan S, Lin Y, Lin W, Piazza GA, Fodstad O, Tan M (2016)
    Immunoregulatory Protein B7-H3 Reprograms Glucose Metabolism in Cancer Cells by ROS-Mediated Stabilization of HIF1α
    Cancer Res, 76 (8), 2231-42
    DOI 10.1158/0008-5472.CAN-15-1538, PubMed 27197253
17. Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH (2016)
    Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer
    Oncotarget, 7 (23), 34907-17
    DOI 10.18632/oncotarget.8995, PubMed 27145458
18. Nunes-Xavier CE, Karlsen KF, Tekle C, Pedersen C, Øyjord T, Hongisto V, Nesland JM, Tan M, Sahlberg KK, Fodstad Ø (2016)
    Decreased expression of B7-H3 reduces the glycolytic capacity and sensitizes breast cancer cells to AKT/mTOR inhibitors
    Oncotarget, 7 (6), 6891-901
    DOI 10.18632/oncotarget.6902, PubMed 26771843
19. Nunes-Xavier CE, Pulido R (2016)
    Global RT-PCR and RT-qPCR Analysis of the mRNA Expression of the Human PTPome
    Methods Mol Biol, 1447, 25-37
    DOI 10.1007/978-1-4939-3746-2_2, PubMed 27514798
20. Seip K, Fleten KG, Barkovskaya A, Nygaard V, Haugen MH, Engesæter BØ, Mælandsmo GM, Prasmickaite L (2016)
    Fibroblast-induced switching to the mesenchymal-like phenotype and PI3K/mTOR signaling protects melanoma cells from BRAF inhibitors
    Oncotarget, 7 (15), 19997-20015
    DOI 10.18632/oncotarget.7671, PubMed 26918352
21. Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K (2016)
    Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer
    Ann Surg Oncol, 24 (3), 721-728
    DOI 10.1245/s10434-016-5621-5, PubMed 27766561

Publications 2015

1. Andersson Y, Engebraaten O, Juell S, Aamdal S, Brunsvig P, Fodstad Ø, Dueland S (2015)
   Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin
   Br J Cancer, 113 (11), 1548-55
   DOI 10.1038/bjc.2015.380, PubMed 26554649
2. Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM (2015)
   Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes
   Clin Exp Metastasis, 32 (8), 755-67
   DOI 10.1007/s10585-015-9742-1, PubMed 26349943
3. Eide N, Faye RS, Høifødt HK, Sandstad B, Qvale G, Faber R, Jebsen P, Kvalheim G, Fodstad Ø (2015)
   Immunomagnetic detection of micrometastatic cells in bone marrow of uveal melanoma patients: a paradox
   Acta Ophthalmol, 93 (1), 59-66
   DOI 10.1111/aos.12462, PubMed 25613126
4. Eide N, Garred Ø, Beiske K, Fodstad Ø (2015)
   Bilateral uveal melanomas with different gene expression detected with 7 years interval
   Acta Ophthalmol, 94 (1), 99-102
   DOI 10.1111/aos.12857, PubMed 26496992
5. Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B (2015)
   Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial
   Trials, 16, 73
   DOI 10.1186/s13063-015-0577-5, PubMed 25872027
6. Fromm B, Trelis M, Hackenberg M, Cantalapiedra F, Bernal D, Marcilla A (2015)
   The revised microRNA complement of Fasciola hepatica reveals a plethora of overlooked microRNAs and evidence for enrichment of immuno-regulatory microRNAs in extracellular vesicles
   Int J Parasitol, 45 (11), 697-702
   DOI 10.1016/j.ijpara.2015.06.002, PubMed 26183562
7. Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH (2015)
   Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer
   BMC Cancer, 15, 543
   DOI 10.1186/s12885-015-1557-6, PubMed 26205955
8. Hektoen HH, Ree AH, Redalen KR, Flatmark K (2015)
   Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells
   J Enzyme Inhib Med Chem, 31 (5), 779-86
   DOI 10.3109/14756366.2015.1069286, PubMed 26244271
9. Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, Singh S, Williams C, Soplop N, Uryu K, Pharmer L, King T, Bojmar L, Davies AE, Ararso Y, Zhang T, Zhang H, Hernandez J, Weiss JM, Dumont-Cole VD, Kramer K et al. (2015)
   Tumour exosome integrins determine organotropic metastasis
   Nature, 527 (7578), 329-35
   DOI 10.1038/nature15756, PubMed 26524530
10. Prasmickaite L, Berge G, Bettum IJ, Aamdal S, Hansson J, Bastholt L, Øijordsbakken M, Boye K, Mælandsmo GM (2015)
    Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial
    Cancer Immunol Immunother, 64 (6), 769-76
    DOI 10.1007/s00262-015-1686-4, PubMed 25832001
11. Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T (2015)
    High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer
    Radiother Oncol, 118 (2), 393-8
    DOI 10.1016/j.radonc.2015.11.031, PubMed 26705680
12. Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR (2015)
    Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies
    Crit Rev Oncol Hematol, 95 (1), 114-24
    DOI 10.1016/j.critrevonc.2015.01.003, PubMed 25624177
13. Repetto-Llamazares AH, Larsen RH, Patzke S, Fleten KG, Didierlaurent D, Pichard A, Pouget JP, Dahle J (2015)
    Targeted Cancer Therapy with a Novel Anti-CD37 Beta-Particle Emitting Radioimmunoconjugate for Treatment of Non-Hodgkin Lymphoma
    PLoS One, 10 (6), e0128816
    DOI 10.1371/journal.pone.0128816, PubMed 26066655
14. Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR (2015)
    MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer
    Br J Radiol, 88 (1051), 20150097
    DOI 10.1259/bjr.20150097, PubMed 25899892
15. Srivastava SK, Bhardwaj A, Arora S, Tyagi N, Singh AP, Carter JE, Scammell JG, Fodstad Ø, Singh S (2015)
    Interleukin-8 is a key mediator of FKBP51-induced melanoma growth, angiogenesis and metastasis
    Br J Cancer, 112 (11), 1772-81
    DOI 10.1038/bjc.2015.154, PubMed 25942396
16. Wendel T, Zhen Y, Suo Z, Bruheim S, Wiedlocha A (2015)
    The novel HSP90 inhibitor NVP-AUY922 shows synergistic anti-leukemic activity with cytarabine in vivo
    Exp Cell Res, 340 (2), 220-6
    DOI 10.1016/j.yexcr.2015.12.017, PubMed 26748184

Publications 2014

1. Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K (2014)
   High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting
   Eur J Cancer, 51 (1), 9-17
   DOI 10.1016/j.ejca.2014.10.020, PubMed 25466510
2. Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø (2014)
   B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome
   BMC Cancer, 14, 602
   DOI 10.1186/1471-2407-14-602, PubMed 25139714
3. Nygren MK, Tekle C, Ingebrigtsen VA, Mäkelä R, Krohn M, Aure MR, Nunes-Xavier CE, Perälä M, Tramm T, Alsner J, Overgaard J, Nesland JM, Borgen E, Børresen-Dale AL, Fodstad Ø, Sahlberg KK, Leivonen SK (2014)
   Identifying microRNAs regulating B7-H3 in breast cancer: the clinical impact of microRNA-29c
   Br J Cancer, 110 (8), 2072-80
   DOI 10.1038/bjc.2014.113, PubMed 24577056
4. Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL et al. (2014)
   Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium
   J Enzyme Inhib Med Chem, 30 (5), 689-721
   DOI 10.3109/14756366.2014.966704, PubMed 25347767
5. Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K (2014)
   Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy
   PLoS One, 9 (2), e89750
   DOI 10.1371/journal.pone.0089750, PubMed 24587009
6. Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y (2014)
   The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells
   J Ovarian Res, 7, 23
   DOI 10.1186/1757-2215-7-23, PubMed 24528603

Publications 2013

1. Bruheim S, Sandvold ML, Mælandsmo GM, Fodstad O (2013)
   Antitumor activity of elacytarabine combined with bevacizumab, cetuximab and trastuzumab in human NSCLC xenografts
   Anticancer Res, 33 (9), 3615-21
   PubMed 24023287
2. Desai S, Liu Z, Yao J, Patel N, Chen J, Wu Y, Ahn EE, Fodstad O, Tan M (2013)
   Heat shock factor 1 (HSF1) controls chemoresistance and autophagy through transcriptional regulation of autophagy-related protein 7 (ATG7)
   J Biol Chem, 288 (13), 9165-76
   DOI 10.1074/jbc.M112.422071, PubMed 23386620
3. Flatmark K, Guldvik IJ, Svensson H, Fleten KG, Flørenes VA, Reed W, Giercksky KE, Fodstad Ø, Andersson Y (2013)
   Immunotoxin targeting EpCAM effectively inhibits peritoneal tumor growth in experimental models of mucinous peritoneal surface malignancies
   Int J Cancer, 133 (6), 1497-506
   DOI 10.1002/ijc.28158, PubMed 23494569
4. Friedman R, Boye K, Flatmark K (2013)
   Molecular modelling and simulations in cancer research
   Biochim Biophys Acta, 1836 (1), 1-14
   DOI 10.1016/j.bbcan.2013.02.001, PubMed 23416097
5. Haugen MH, Johansen HT, Pettersen SJ, Solberg R, Brix K, Flatmark K, Maelandsmo GM (2013)
   Nuclear legumain activity in colorectal cancer
   PLoS One, 8 (1), e52980
   DOI 10.1371/journal.pone.0052980, PubMed 23326369
6. Kongsgaard A, Borgen E, Mælandsmo GM, Flatmark K, Le H, Josefsen D, Solvoll I, Schirmer CB, Helland Å, Jørgensen L, Brustugun OT, Fodstad Ø, Boye K (2013)
   Clinical significance of disseminated tumour cells in non-small cell lung cancer
   Br J Cancer, 109 (5), 1264-70
   DOI 10.1038/bjc.2013.450, PubMed 23942067
7. Ragnum HB, Røe K, Holm R, Vlatkovic L, Nesland JM, Aarnes EK, Ree AH, Flatmark K, Seierstad T, Lilleby W, Lyng H (2013)
   Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
   Int J Radiat Oncol Biol Phys, 87 (4), 753-60
   DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332
8. Schee K, Lorenz S, Worren MM, Günther CC, Holden M, Hovig E, Fodstad O, Meza-Zepeda LA, Flatmark K (2013)
   Deep Sequencing the MicroRNA Transcriptome in Colorectal Cancer
   PLoS One, 8 (6), e66165
   DOI 10.1371/journal.pone.0066165, PubMed 23824282
9. Sørensen O, Andersen AM, Kristian A, Giercksky KE, Flatmark K (2013)
   Impact of hyperthermia on pharmacokinetics of intraperitoneal mitomycin C in rats investigated by microdialysis
   J Surg Oncol, 109 (6), 521-6
   DOI 10.1002/jso.23527, PubMed 24347444
10. Wang P, Suo Z, Wang M, Høifødt HK, Fodstad O, Gaudernack G, Kvalheim G (2013)
    In vitro and in vivo properties of CD133 expressing cells from human lung cancer cell lines
    Exp Hematol Oncol, 2 (1), 16
    DOI 10.1186/2162-3619-2-16, PubMed 23738757
11. Zhai H, Fesler A, Schee K, Fodstad O, Flatmark K, Ju J (2013)
    Clinical significance of long intergenic noncoding RNA-p21 in colorectal cancer
    Clin Colorectal Cancer, 12 (4), 261-6
    DOI 10.1016/j.clcc.2013.06.003, PubMed 24012455

Publications 2012

1. Boye K, Nesland JM, Sandstad B, Haugland Haugen M, Mælandsmo GM, Flatmark K (2012)
   EMMPRIN is associated with S100A4 and predicts patient outcome in colorectal cancer
   Br J Cancer, 107 (4), 667-74
   DOI 10.1038/bjc.2012.293, PubMed 22782346
2. Brusegard K, Stavnes HT, Nymoen DA, Flatmark K, Trope CG, Davidson B (2012)
   Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
   Virchows Arch, 460 (2), 193-202
   DOI 10.1007/s00428-011-1191-x, PubMed 22249560
3. Cejudo-Marín R, Tárrega C, Nunes-Xavier CE, Pulido R (2012)
   Caspase-3 cleavage of DUSP6/MKP3 at the interdomain region generates active MKP3 fragments that regulate ERK1/2 subcellular localization and function
   J Mol Biol, 420 (1-2), 128-38
   DOI 10.1016/j.jmb.2012.04.004, PubMed 22504224
4. Ding Y, Liu Z, Desai S, Zhao Y, Liu H, Pannell LK, Yi H, Wright ER, Owen LB, Dean-Colomb W, Fodstad O, Lu J, LeDoux SP, Wilson GL, Tan M (2012)
   Receptor tyrosine kinase ErbB2 translocates into mitochondria and regulates cellular metabolism
   Nat Commun, 3, 1271
   DOI 10.1038/ncomms2236, PubMed 23232401
5. Eide N, Hoifødt HK, Nesland JM, Faye RS, Qvale GA, Faber RT, Jebsen P, Kvalheim G, Fodstad Ø (2012)
   Disseminated tumour cells in bone marrow of patients with uveal melanoma
   Acta Ophthalmol, 91 (4), 343-8
   DOI 10.1111/j.1755-3768.2012.02449.x, PubMed 22632270
6. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O (2012)
   B7-H3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer
   Int J Cancer, 131 (11), 2528-36
   DOI 10.1002/ijc.27566, PubMed 22473715
7. Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M (2012)
   miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance
   J Biol Chem, 288 (6), 4334-45
   DOI 10.1074/jbc.M112.419168, PubMed 23255607
8. Ree AH, Kristensen AT, Saelen MG, de Wijn R, Edvardsen H, Jovanovic J, Abrahamsen TW, Dueland S, Flatmark K (2012)
   Tumor phosphatidylinositol-3-kinase signaling and development of metastatic disease in locally advanced rectal cancer
   PLoS One, 7 (11), e50806
   DOI 10.1371/journal.pone.0050806, PubMed 23226389
9. Saelen MG, Ree AH, Kristian A, Fleten KG, Furre T, Hektoen HH, Flatmark K (2012)
   Radiosensitization by the histone deacetylase inhibitor vorinostat under hypoxia and with capecitabine in experimental colorectal carcinoma
   Radiat Oncol, 7, 165
   DOI 10.1186/1748-717X-7-165, PubMed 23017053
10. Schee K, Boye K, Abrahamsen TW, Fodstad Ø, Flatmark K (2012)
    Clinical relevance of microRNA miR-21, miR-31, miR-92a, miR-101, miR-106a and miR-145 in colorectal cancer
    BMC Cancer, 12, 505
    DOI 10.1186/1471-2407-12-505, PubMed 23121918
11. Schee K, Flatmark K, Holm R, Boye K, Paus E (2012)
    Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients (vol 33, pg 73, 2012)
    Tumor Biol., 33 (4), 1263-1264
    DOI 10.1007/s13277-012-0407-2
12. Sørensen O, Flatmark K, Reed W, Wiig JN, Dueland S, Giercksky KE, Larsen SG (2012)
    Evaluation of complete cytoreductive surgery and two intraperitoneal chemotherapy techniques in Pseudomyxoma peritonei
    Eur J Surg Oncol, 38 (10), 969-76
    DOI 10.1016/j.ejso.2012.06.552, PubMed 22763244
13. Vincent AJ, Ren S, Harris LG, Devine DJ, Samant RS, Fodstad O, Shevde LA (2012)
    Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance
    FEBS Lett, 586 (19), 3429-34
    DOI 10.1016/j.febslet.2012.07.063, PubMed 22858377

Publications 2011

1. Bratland A, Dueland S, Hollywood D, Flatmark K, Ree AH (2011)
   Gastrointestinal toxicity of vorinostat: reanalysis of phase 1 study results with emphasis on dose-volume effects of pelvic radiotherapy
   Radiat Oncol, 6, 33
   DOI 10.1186/1748-717X-6-33, PubMed 21473790
2. Bruheim S, Kristian A, Uenaka T, Suo Z, Tsuruoka A, Nesland JM, Fodstad Ø (2011)
   Antitumour activity of oral E7080, a novel inhibitor of multiple tyrosine kinases, in human sarcoma xenografts
   Int J Cancer, 129 (3), 742-50
   DOI 10.1002/ijc.25922, PubMed 21225632
3. Flatmark K, Borgen E, Nesland JM, Rasmussen H, Johannessen HO, Bukholm I, Rosales R, Hårklau L, Jacobsen HJ, Sandstad B, Boye K, Fodstad Ø (2011)
   Disseminated tumour cells as a prognostic biomarker in colorectal cancer
   Br J Cancer, 104 (9), 1434-9
   DOI 10.1038/bjc.2011.97, PubMed 21448171
4. Hjortland GO, Meza-Zepeda LA, Beiske K, Ree AH, Tveito S, Hoifodt H, Bohler PJ, Hole KH, Myklebost O, Fodstad O, Smeland S, Hovig E (2011)
   Genome wide single cell analysis of chemotherapy resistant metastatic cells in a case of gastroesophageal adenocarcinoma
   BMC Cancer, 11, 455
   DOI 10.1186/1471-2407-11-455, PubMed 22014070
5. Liu H, Tekle C, Chen YW, Kristian A, Zhao Y, Zhou M, Liu Z, Ding Y, Wang B, Mælandsmo GM, Nesland JM, Fodstad O, Tan M (2011)
   B7-H3 silencing increases paclitaxel sensitivity by abrogating Jak2/Stat3 phosphorylation
   Mol Cancer Ther, 10 (6), 960-71
   DOI 10.1158/1535-7163.MCT-11-0072, PubMed 21518725
6. Nygren MK, Tekle C, Ingebrigtsen VA, Fodstad O (2011)
   B7-H3 and its relevance in cancer; immunological and non-immunological perspectives
   Front Biosci (Elite Ed), 3 (3), 989-93
   DOI 10.2741/e304, PubMed 21622107
7. Risberg K, Fodstad Ø, Andersson Y (2011)
   Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma
   PLoS One, 6 (9), e24012
   DOI 10.1371/journal.pone.0024012, PubMed 21915275
8. Risberg K, Guldvik IJ, Palchaudhuri R, Xi Y, Ju J, Fodstad O, Hergenrother PJ, Andersson Y (2011)
   Triphenylmethyl derivatives enhances the anticancer effect of immunotoxins
   J Immunother, 34 (5), 438-47
   DOI 10.1097/CJI.0b013e31821e00ae, PubMed 21577141
9. Saelen MG, Flatmark K, Folkvord S, de Wijn R, Rasmussen H, Fodstad Ø, Ree AH (2011)
   Tumor kinase activity in locally advanced rectal cancer: angiogenic signaling and early systemic dissemination
   Angiogenesis, 14 (4), 481-9
   DOI 10.1007/s10456-011-9231-3, PubMed 21833622
10. Schee K, Flatmark K, Holm R, Boye K, Paus E (2011)
    Investigation of nonspecific cross-reacting antigen 2 as a prognostic biomarker in bone marrow plasma from colorectal cancer patients
    Tumour Biol, 33 (1), 73-83
    DOI 10.1007/s13277-011-0247-5, PubMed 22006279
11. Tekle C, Nygren MK, Chen YW, Dybsjord I, Nesland JM, Maelandsmo GM, Fodstad O (2011)
    B7-H3 contributes to the metastatic capacity of melanoma cells by modulation of known metastasis-associated genes
    Int J Cancer, 130 (10), 2282-90
    DOI 10.1002/ijc.26238, PubMed 21671471
12. Tveito S, Andersen K, Kåresen R, Fodstad Ø (2011)
    Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles
    Breast Cancer Res, 13 (4), R75
    DOI 10.1186/bcr2922, PubMed 21816090
13. Wang B, Howel P, Bruheim S, Ju J, Owen LB, Fodstad O, Xi Y (2011)
    Systematic evaluation of three microRNA profiling platforms: microarray, beads array, and quantitative real-time PCR array
    PLoS One, 6 (2), e17167
    DOI 10.1371/journal.pone.0017167, PubMed 21347261
14. Wiig JN, Larsen SG, Dueland S, Flatmark K, Giercksky KE (2011)
    Salvage surgery for locally recurrent rectal cancer: total mesorectal excision during the primary operation does not influence the outcome
    Colorectal Dis, 13 (5), 506-11
    DOI 10.1111/j.1463-1318.2010.02256.x, PubMed 20236148
15. Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, Liu B, Fodstad O, Chen J, Wu Y, Price JE, Tan M (2011)
    Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism
    Cancer Res, 71 (13), 4585-97
    DOI 10.1158/0008-5472.CAN-11-0127, PubMed 21498634
16. Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL, Tan M (2011)
    Emerging metabolic targets in cancer therapy
    Front Biosci (Landmark Ed), 16 (5), 1844-60
    DOI 10.2741/3826, PubMed 21196269

Publications 2010

1. Berge G, Costea DE, Berg M, Rasmussen H, Grotterød I, Lothe RA, Mælandsmo GM, Flatmark K (2010)
   Coexpression and nuclear colocalization of metastasis-promoting protein S100A4 and p53 without mutual regulation in colorectal carcinoma
   Amino Acids, 41 (4), 875-84
   DOI 10.1007/s00726-010-0514-6, PubMed 20191297
2. Bergman AM, Adema AD, Balzarini J, Bruheim S, Fichtner I, Noordhuis P, Fodstad O, Myhren F, Sandvold ML, Hendriks HR, Peters GJ (2010)
   Antiproliferative activity, mechanism of action and oral antitumor activity of CP-4126, a fatty acid derivative of gemcitabine, in in vitro and in vivo tumor models
   Invest New Drugs, 29 (3), 456-66
   DOI 10.1007/s10637-009-9377-7, PubMed 20066470
3. Boye K, Nesland JM, Sandstad B, Mælandsmo GM, Flatmark K (2010)
   Nuclear S100A4 is a novel prognostic marker in colorectal cancer
   Eur J Cancer, 46 (16), 2919-25
   DOI 10.1016/j.ejca.2010.07.013, PubMed 20719498
4. Briggs JJ, Haugen MH, Johansen HT, Riker AI, Abrahamson M, Fodstad Ø, Maelandsmo GM, Solberg R (2010)
   Cystatin E/M suppresses legumain activity and invasion of human melanoma
   BMC Cancer, 10, 17
   DOI 10.1186/1471-2407-10-17, PubMed 20074384
5. Flatmark K, Davidson B, Kristian A, Stavnes HT, Førsund M, Reed W (2010)
   Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
   Hum Pathol, 41 (8), 1109-19
   DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618
6. Flatmark K, Ree AH (2010)
   Radiosensitizing drugs: lessons to be learned from the oxaliplatin story
   J Clin Oncol, 28 (29), e577-8; author reply e581-3
   DOI 10.1200/JCO.2010.30.0921, PubMed 20733124
7. Folkvord S, Flatmark K, Dueland S, de Wijn R, Grøholt KK, Hole KH, Nesland JM, Ruijtenbeek R, Boender PJ, Johansen M, Giercksky KE, Ree AH (2010)
   Prediction of response to preoperative chemoradiotherapy in rectal cancer by multiplex kinase activity profiling
   Int J Radiat Oncol Biol Phys, 78 (2), 555-62
   DOI 10.1016/j.ijrobp.2010.04.036, PubMed 20675069
8. Mercapide J, Rappa G, Anzanello F, King J, Fodstad O, Lorico A (2010)
   Primary gene-engineered neural stem/progenitor cells demonstrate tumor-selective migration and antitumor effects in glioma
   Int J Cancer, 126 (5), 1206-15
   DOI 10.1002/ijc.24809, PubMed 19653275
9. Olberg DE, Cuthbertson A, Solbakken M, Arukwe JM, Qu H, Kristian A, Bruheim S, Hjelstuen OK (2010)
   Radiosynthesis and biodistribution of a prosthetic group (¹⁸F-FENMA) conjugated to cyclic RGD peptides
   Bioconjug Chem, 21 (12), 2297-304
   DOI 10.1021/bc1003229, PubMed 21070000
10. Paus E, Haugen MH, Olsen KH, Flatmark K, Maelandsmo GM, Nilsson O, Röijer E, Lundin M, Fermér C, Samsonova M, Lebedin Y, Stigbrand T (2010)
    TD-11 workshop report: characterization of monoclonal antibodies to S100 proteins
    Tumour Biol, 32 (1), 1-12
    DOI 10.1007/s13277-010-0073-1, PubMed 20652782
11. Prasmickaite L, Skrbo N, Høifødt HK, Suo Z, Engebråten O, Gullestad HP, Aamdal S, Fodstad Ø, Maelandsmo GM (2010)
    Human malignant melanoma harbours a large fraction of highly clonogenic cells that do not express markers associated with cancer stem cells
    Pigment Cell Melanoma Res, 23 (3), 449-51
    DOI 10.1111/j.1755-148X.2010.00690.x, PubMed 20236249
12. Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K (2010)
    Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study
    Lancet Oncol, 11 (5), 459-64
    DOI 10.1016/S1470-2045(10)70058-9, PubMed 20378407
13. Risberg K, Fodstad O, Andersson Y (2010)
    Anti-melanoma activity of the 9.2.27PE immunotoxin in dacarbazine resistant cells
    J Immunother, 33 (3), 272-8
    DOI 10.1097/CJI.0b013e3181c54991, PubMed 20445347
14. Risberg K, Fodstad O, Andersson Y (2010)
    Immunotoxins: a promising treatment modality for metastatic melanoma?
    Ochsner J, 10 (3), 193-9
    PubMed 21603377
15. Schee K, Fodstad Ø, Flatmark K (2010)
    MicroRNAs as biomarkers in colorectal cancer
    Am J Pathol, 177 (4), 1592-9
    DOI 10.2353/ajpath.2010.100024, PubMed 20829435
16. Sørensen O, Andersen A, Olsen H, Alexandr K, Ekstrøm PO, Giercksky KE, Flatmark K (2010)
    Validation and use of microdialysis for determination of pharmacokinetic properties of the chemotherapeutic agent mitomycin C - an experimental study
    BMC Cancer, 10, 469
    DOI 10.1186/1471-2407-10-469, PubMed 20809961
17. Tárrega C, Nunes-Xavier C, Cejudo-Marín R, Martín-Pérez J, Pulido R (2010)
    Studying the regulation of MAP Kinase by MAP Kinase phosphatases in vitro and in cell systems
    Methods Mol Biol, 661, 305-21
    DOI 10.1007/978-1-60761-795-2_18, PubMed 20811991
18. Wiiger MT, Gehrken HB, Fodstad Ø, Maelandsmo GM, Andersson Y (2010)
    A novel human recombinant single-chain antibody targeting CD166/ALCAM inhibits cancer cell invasion in vitro and in vivo tumour growth
    Cancer Immunol Immunother, 59 (11), 1665-74
    DOI 10.1007/s00262-010-0892-3, PubMed 20635083
19. Zhou M, Liu Z, Zhao Y, Ding Y, Liu H, Xi Y, Xiong W, Li G, Lu J, Fodstad O, Riker AI, Tan M (2010)
    MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of pro-apoptotic Bcl-2 antagonist killer 1 (Bak1) expression
    J Biol Chem, 285 (28), 21496-507
    DOI 10.1074/jbc.M109.083337, PubMed 20460378
20. Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, Ledoux SP, Tan M (2010)
    Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol
    Mol Cancer, 9, 33
    DOI 10.1186/1476-4598-9-33, PubMed 20144215

Publications 2009

1. Andersson Y, Engebraaten O, Fodstad Ø (2009)
   Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo
   Br J Cancer, 101 (8), 1307-15
   DOI 10.1038/sj.bjc.6605312, PubMed 19773757
2. Bergamaschi A, Hjortland GO, Triulzi T, Sørlie T, Johnsen H, Ree AH, Russnes HG, Tronnes S, Maelandsmo GM, Fodstad O, Borresen-Dale AL, Engebraaten O (2009)
   Molecular profiling and characterization of luminal-like and basal-like in vivo breast cancer xenograft models
   Mol Oncol, 3 (5-6), 469-82
   DOI 10.1016/j.molonc.2009.07.003, PubMed 19713161
3. Bratland A, Boender PJ, Høifødt HK, Østensen IH, Ruijtenbeek R, Wang MY, Berg JP, Lilleby W, Fodstad Ø, Ree AH (2009)
   Osteoblast-induced EGFR/ERBB2 signaling in androgen-sensitive prostate carcinoma cells characterized by multiplex kinase activity profiling
   Clin Exp Metastasis, 26 (5), 485-96
   DOI 10.1007/s10585-009-9248-9, PubMed 19294521
4. Bruheim S, Xi Y, Ju J, Fodstad O (2009)
   Gene expression profiles classify human osteosarcoma xenografts according to sensitivity to doxorubicin, cisplatin, and ifosfamide
   Clin Cancer Res, 15 (23), 7161-9
   DOI 10.1158/1078-0432.CCR-08-2816, PubMed 19920113
5. Chowdhury UR, Samant RS, Fodstad O, Shevde LA (2009)
   Emerging role of nuclear protein 1 (NUPR1) in cancer biology
   Cancer Metastasis Rev, 28 (1-2), 225-32
   DOI 10.1007/s10555-009-9183-x, PubMed 19153668
6. Eide N, Faye RS, Høifødt HK, Øvergaard R, Jebsen P, Kvalheim G, Fodstad Ø (2009)
   Immunomagnetic detection of micrometastatic cells in bone marrow in uveal melanoma patients
   Acta Ophthalmol, 87 (8), 830-6
   DOI 10.1111/j.1755-3768.2008.01378.x, PubMed 19055657
7. Engebraaten O, Trikha M, Juell S, Garman-Vik S, Fodstad Ø (2009)
   Inhibition of in vivo tumour growth by the blocking of host alpha(v)beta3 and alphaII(b)beta3 integrins
   Anticancer Res, 29 (1), 131-7
   PubMed 19331142
8. Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K (2009)
   Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status
   Int J Radiat Oncol Biol Phys, 74 (2), 546-52
   DOI 10.1016/j.ijrobp.2009.01.068, PubMed 19427556
9. Hoyem S, Bruheim S, Maelandsmo G, Standal M, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
   Didanosine ester prodrugs: Synthesis, albumin binding properties and pharmacokinetic studies in rats (vol 44, pg 3874, 2009)
   Eur. J. Med. Chem., 44 (11), 4786
   DOI 10.1016/j.ejmech.2009.08.006
10. Høyem S, Bruheim S, Maelandsmo G, Olberg DE, Brudeli B, Asberg A, Klaveness J, Rongved P (2009)
    Didanosine ester prodrugs: synthesis, albumin binding properties and pharmacokinetic studies in rats
    Eur J Med Chem, 44 (10), 3874-9
    DOI 10.1016/j.ejmech.2009.04.008, PubMed 19433342
11. Liu S, Howell P, Ren S, Fodstad O, Riker AI (2009)
    The 14-3-3sigma gene promoter is methylated in both human melanocytes and melanoma
    BMC Cancer, 9, 162
    DOI 10.1186/1471-2407-9-162, PubMed 19473536
12. Liu S, Howell P, Ren S, Fodstad O, Zhang G, Samant R, Shevde L, Xi Y, Pannell LK, Riker AI (2009)
    Expression and functional analysis of the WAP four disulfide core domain 1 gene in human melanoma
    Clin Exp Metastasis, 26 (7), 739-49
    DOI 10.1007/s10585-009-9273-8, PubMed 19488830
13. Maelandsmo GM, Flørenes VA, Nguyen MT, Flatmark K, Davidson B (2009)
    Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
    Tumour Biol, 30 (1), 15-25
    DOI 10.1159/000199447, PubMed 19194111
14. Ren S, Liu S, Howell PM, Zhang G, Pannell L, Samant R, Shevde-Samant L, Tucker JA, Fodstad O, Riker AI (2009)
    Functional characterization of the progestagen-associated endometrial protein gene in human melanoma
    J Cell Mol Med, 14 (6B), 1432-42
    DOI 10.1111/j.1582-4934.2009.00922.x, PubMed 19799645
15. Risberg K, Fodstad Ø, Andersson Y (2009)
    The melanoma specific 9.2.27PE immunotoxin efficiently kills melanoma cells in vitro
    Int J Cancer, 125 (1), 23-33
    DOI 10.1002/ijc.24317, PubMed 19350633
16. Seierstad T, Hole KH, Saelen E, Ree AH, Flatmark K, Malinen E (2009)
    MR-guided simultaneous integrated boost in preoperative radiotherapy of locally advanced rectal cancer following neoadjuvant chemotherapy
    Radiother Oncol, 93 (2), 279-84
    DOI 10.1016/j.radonc.2009.08.046, PubMed 19800704
17. Song B, Wang Y, Xi Y, Kudo K, Bruheim S, Botchkina GI, Gavin E, Wan Y, Formentini A, Kornmann M, Fodstad O, Ju J (2009)
    Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells
    Oncogene, 28 (46), 4065-74
    DOI 10.1038/onc.2009.274, PubMed 19734943
18. Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D, Fodstad O, Tan M (2009)
    Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth
    Oncogene, 28 (42), 3689-701
    DOI 10.1038/onc.2009.229, PubMed 19668225

Publications 2008

1. Brunsvig PF, Flatmark K, Aamdal S, Høifødt H, Le H, Jakobsen E, Sandstad B, Fodstad O (2008)
   Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients
   Lung Cancer, 61 (2), 170-6
   DOI 10.1016/j.lungcan.2007.12.018, PubMed 18261824
2. Faye RS, Paus E, Maelandsmo GM, Berner A, Høifødt HK, Fodstad Ø, Aamdal S (2008)
   S100B in bone marrow aspirates in healthy individuals and malignant melanoma patients
   Melanoma Res, 18 (2), 134-40
   DOI 10.1097/CMR.0b013e3282f623d9, PubMed 18337650
3. Haugen MH, Flatmark K, Mikalsen SO, Malandsmo GM (2008)
   The metastasis-associated protein S100A4 exists in several charged variants suggesting the presence of posttranslational modifications
   BMC Cancer, 8, 172
   DOI 10.1186/1471-2407-8-172, PubMed 18554396
4. Kristensen AT, Wiig JN, Larsen SG, Giercksky KE, Ekstrøm PO (2008)
   Molecular detection (k-ras) of exfoliated tumour cells in the pelvis is a prognostic factor after resection of rectal cancer?
   BMC Cancer, 8, 213
   DOI 10.1186/1471-2407-8-213, PubMed 18655729
5. Ree AH, Folkvord S, Flatmark K (2008)
   HDAC2 deficiency and histone acetylation
   Nat Genet, 40 (7), 812-3; author reply 813
   DOI 10.1038/ng0708-812, PubMed 18583969
6. Seierstad T, Røe K, Sitter B, Halgunset J, Flatmark K, Ree AH, Olsen DR, Gribbestad IS, Bathen TF (2008)
   Principal component analysis for the comparison of metabolic profiles from human rectal cancer biopsies and colorectal xenografts using high-resolution magic angle spinning 1H magnetic resonance spectroscopy
   Mol Cancer, 7, 33
   DOI 10.1186/1476-4598-7-33, PubMed 18439252

Publications 2007

1. Bauer NN, Chen YW, Samant RS, Shevde LA, Fodstad O (2007)
   Rac1 activity regulates proliferation of aggressive metastatic melanoma
   Exp Cell Res, 313 (18), 3832-9
   DOI 10.1016/j.yexcr.2007.08.017, PubMed 17904119
2. Cekaite L, Peng Q, Reiner A, Shahzidi S, Tveito S, Furre IE, Hovig E (2007)
   Mapping of oxidative stress responses of human tumor cells following photodynamic therapy using hexaminolevulinate
   BMC Genomics, 8, 273
   DOI 10.1186/1471-2164-8-273, PubMed 17692132
3. Flatmark K, Reed W, Halvorsen T, Sørensen O, Wiig JN, Larsen SG, Fodstad Ø, Giercksky KE (2007)
   Pseudomyxoma peritonei--two novel orthotopic mouse models portray the PMCA-I histopathologic subtype
   BMC Cancer, 7, 116
   DOI 10.1186/1471-2407-7-116, PubMed 17603904
4. Fodstad Ø (2007)
   [The 75th anniversary of the Radium Hospital]
   Tidsskr Nor Laegeforen, 127 (13), 1800-1
   PubMed 17599133
5. Folkvord S, Flatmark K, Seierstad T, Røe K, Rasmussen H, Ree AH (2007)
   Inhibitory effects of oxaliplatin in experimental radiation treatment of colorectal carcinoma: does oxaliplatin improve 5-fluorouracil-dependent radiosensitivity?
   Radiother Oncol, 86 (3), 428-34
   DOI 10.1016/j.radonc.2007.10.012, PubMed 18006097
6. Lillehammer T, Engesaeter BO, Prasmickaite L, Maelandsmo GM, Fodstad O, Engebraaten O (2007)
   Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines
   J Gene Med, 9 (6), 440-51
   DOI 10.1002/jgm.1036, PubMed 17410615
7. Seierstad T, Folkvord S, Røe K, Flatmark K, Skretting A, Olsen DR (2007)
   Early changes in apparent diffusion coefficient predict the quantitative antitumoral activity of capecitabine, oxaliplatin, and irradiation in HT29 xenografts in athymic nude mice
   Neoplasia, 9 (5), 392-400
   DOI 10.1593/neo.07154, PubMed 17534444
8. Thies A, Mauer S, Fodstad O, Schumacher U (2007)
   Clinically proven markers of metastasis predict metastatic spread of human melanoma cells engrafted in scid mice
   Br J Cancer, 96 (4), 609-16
   DOI 10.1038/sj.bjc.6603594, PubMed 17262079
9. Tveito S, Maelandsmo GM, Hoifodt HK, Rasmussen H, Fodstad O (2007)
   Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value
   Clin Exp Metastasis, 24 (5), 317-27
   DOI 10.1007/s10585-006-9052-8, PubMed 17530423

Publications 2006

1. Andersson Y, Le H, Juell S, Fodstad Ø (2006)
   AMP-activated protein kinase protects against anti-epidermal growth factor receptor-Pseudomonas exotoxin A immunotoxin-induced MA11 breast cancer cell death
   Mol Cancer Ther, 5 (4), 1050-9
   DOI 10.1158/1535-7163.MCT-05-0318, PubMed 16648577
2. Boye K, Andersen K, Tveito S, Øyjord T, Maelandsmo GM (2006)
   Interferon-gamma-induced suppression of S100A4 transcription is mediated by the class II transactivator
   Tumour Biol, 28 (1), 27-35
   DOI 10.1159/000097700, PubMed 17143014
3. Engesaeter BØ, Tveito S, Bonsted A, Engebraaten O, Berg K, Maelandsmo GM (2006)
   Photochemical treatment with endosomally localized photosensitizers enhances the number of adenoviruses in the nucleus
   J Gene Med, 8 (6), 707-18
   DOI 10.1002/jgm.902, PubMed 16518880
4. Flatmark K, Nome RV, Folkvord S, Bratland A, Rasmussen H, Ellefsen MS, Fodstad Ø, Ree AH (2006)
   Radiosensitization of colorectal carcinoma cell lines by histone deacetylase inhibition
   Radiat Oncol, 1, 25
   DOI 10.1186/1748-717X-1-25, PubMed 16887021
5. Jiang WG, Davies G, Kynaston H, Mason MD, Fodstad O (2006)
   Does the PGC-1/PPARgamma pathway play a role in Com-1/p8 mediated cell growth inhibition in prostate cancer?
   Int J Mol Med, 18 (6), 1169-75
   PubMed 17089023
6. Jiang WG, Davies G, Martin TA, Kynaston H, Mason MD, Fodstad O (2006)
   Com-1/p8 acts as a putative tumour suppressor in prostate cancer
   Int J Mol Med, 18 (5), 981-6
   PubMed 17016631
7. Mbeunkui F, Fodstad O, Pannell LK (2006)
   Secretory protein enrichment and analysis: an optimized approach applied on cancer cell lines using 2D LC-MS/MS
   J Proteome Res, 5 (4), 899-906
   DOI 10.1021/pr050375p, PubMed 16602697
8. Ree AH, Stokke T, Bratland A, Patzke S, Nome RV, Folkvord S, Meza-Zepeda LA, Flatmark K, Fodstad O, Andersson Y (2006)
   DNA damage responses in cell cycle G2 phase and mitosis--tracking and targeting
   Anticancer Res, 26 (3A), 1909-16
   PubMed 16827124

Publications 2005

1. Bjørnland K, Flatmark K, Pettersen S, Aaasen AO, Fodstad O, Maelandsmo GM (2005)
   Matrix metalloproteinases participate in osteosarcoma invasion
   J Surg Res, 127 (2), 151-6
   DOI 10.1016/j.jss.2004.12.016, PubMed 16083752
2. Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O (2005)
   Hematogenous micrometastases in osteosarcoma patients
   Clin Cancer Res, 11 (13), 4666-73
   DOI 10.1158/1078-0432.CCR-05-0165, PubMed 16000559
3. Engesaeter BØ, Bonsted A, Berg K, Høgset A, Engebråten O, Fodstad Ø, Curiel DT, Maelandsmo GM (2005)
   PCI-enhanced adenoviral transduction employs the known uptake mechanism of adenoviral particles
   Cancer Gene Ther, 12 (5), 439-48
   DOI 10.1038/sj.cgt.7700808, PubMed 15678152
4. Hinselwood DC, Abrahamsen TW, Ekstrøm PO (2005)
   BRAF mutation detection and identification by cycling temperature capillary electrophoresis
   Electrophoresis, 26 (13), 2553-61
   DOI 10.1002/elps.200410427, PubMed 15948220
5. Holthe MR, Andersson Y, Lyberg T (2005)
   Lack of proinflammatory effects of free fatty acids on human umbilical cord vein endothelial cells and leukocytes
   Acta Obstet Gynecol Scand, 84 (7), 672-8
   DOI 10.1111/j.0001-6349.2005.00799.x, PubMed 15954878
6. Jiang WG, Davies G, Fodstad O (2005)
   Com-1/P8 in oestrogen regulated growth of breast cancer cells, the ER-beta connection
   Biochem Biophys Res Commun, 330 (1), 253-62
   DOI 10.1016/j.bbrc.2005.02.157, PubMed 15781258
7. Jiang WG, Watkins G, Douglas-Jones A, Mokbel K, Mansel RE, Fodstad O (2005)
   Expression of Com-1/P8 in human breast cancer and its relevance to clinical outcome and ER status
   Int J Cancer, 117 (5), 730-7
   DOI 10.1002/ijc.21221, PubMed 15957166
8. Lillehammer T, Tveito S, Engesaeter BO, Fodstad O, Maelandsmo GM, Engebraaten O (2005)
   Melanoma-specific expression in first-generation adenoviral vectors in vitro and in vivo -- use of the human tyrosinase promoter with human enhancers
   Cancer Gene Ther, 12 (11), 864-72
   DOI 10.1038/sj.cgt.7700852, PubMed 15891771
9. Lorico A, Bratbak D, Meyer J, Kunke D, Krauss S, Plott WE, Solodushko V, Baum C, Fodstad O, Rappa G (2005)
   Gamma-glutamylcysteine synthetase and L-buthionine-(S,R)-sulfoximine: a new selection strategy for gene-transduced neural and hematopoietic stem/progenitor cells
   Hum Gene Ther, 16 (6), 711-24
   DOI 10.1089/hum.2005.16.711, PubMed 15960602
10. Lund T, Stokke T, Olsen ØE, Fodstad Ø (2005)
    Garlic arrests MDA-MB-435 cancer cells in mitosis, phosphorylates the proapoptotic BH3-only protein BimEL and induces apoptosis
    Br J Cancer, 92 (9), 1773-81
    DOI 10.1038/sj.bjc.6602537, PubMed 15827557
11. Matsumoto T, Bohman S, Dixelius J, Berge T, Dimberg A, Magnusson P, Wang L, Wikner C, Qi JH, Wernstedt C, Wu J, Bruheim S, Mugishima H, Mukhopadhyay D, Spurkland A, Claesson-Welsh L (2005)
    VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis
    EMBO J, 24 (13), 2342-53
    DOI 10.1038/sj.emboj.7600709, PubMed 15962004
12. Nome RV, Bratland A, Harman G, Fodstad O, Andersson Y, Ree AH (2005)
    Cell cycle checkpoint signaling involved in histone deacetylase inhibition and radiation-induced cell death
    Mol Cancer Ther, 4 (8), 1231-8
    DOI 10.1158/1535-7163.MCT-04-0304, PubMed 16093439

Publications 2004

1. Andersen K, Nesland JM, Holm R, Flørenes VA, Fodstad Ø, Maelandsmo GM (2004)
   Expression of S100A4 combined with reduced E-cadherin expression predicts patient outcome in malignant melanoma
   Mod Pathol, 17 (8), 990-7
   DOI 10.1038/modpathol.3800151, PubMed 15133476
2. Andersson Y, Juell S, Fodstad Ø (2004)
   Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin
   Int J Cancer, 112 (3), 475-83
   DOI 10.1002/ijc.20371, PubMed 15382075
3. Bergman AM, Kuiper CM, Noordhuis P, Smid K, Voorn DA, Comijn EM, Myhren F, Sandvold ML, Hendriks HR, Fodstad O, Breistøl K, Peters GJ (2004)
   Antiproliferative activity and mechanism of action of fatty acid derivatives of gemcitabine in leukemia and solid tumor cell lines and in human xenografts
   Nucleosides Nucleotides Nucleic Acids, 23 (8-9), 1329-33
   DOI 10.1081/NCN-200027579, PubMed 15571253
4. Bruheim S, Bruland OS, Breistol K, Maelandsmo GM, Fodstad O (2004)
   Human osteosarcoma xenografts and their sensitivity to chemotherapy
   Pathol Oncol Res, 10 (3), 133-41
   DOI 10.1007/BF03033741, PubMed 15448748
5. Choesmel V, Anract P, Høifødt H, Thiery JP, Blin N (2004)
   A relevant immunomagnetic assay to detect and characterize epithelial cell adhesion molecule-positive cells in bone marrow from patients with breast carcinoma: immunomagnetic purification of micrometastases
   Cancer, 101 (4), 693-703
   DOI 10.1002/cncr.20391, PubMed 15305398
6. Faye RS, Aamdal S, Høifødt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad Ø (2004)
   Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients
   Clin Cancer Res, 10 (12 Pt 1), 4134-9
   DOI 10.1158/1078-0432.CCR-03-0408, PubMed 15217950
7. Flatmark K, Maelandsmo GM, Martinsen M, Rasmussen H, Fodstad Ø (2004)
   Twelve colorectal cancer cell lines exhibit highly variable growth and metastatic capacities in an orthotopic model in nude mice
   Eur J Cancer, 40 (10), 1593-8
   DOI 10.1016/j.ejca.2004.02.023, PubMed 15196545
8. Flatmark K, Maelandsmo GM, Mikalsen SO, Nustad K, Varaas T, Rasmussen H, Meling GI, Fodstad Ø, Paus E (2004)
   Immunofluorometric assay for the metastasis-related protein S100A4: release of S100A4 from normal blood cells prohibits the use of S100A4 as a tumor marker in plasma and serum
   Tumour Biol, 25 (1-2), 31-40
   DOI 10.1159/000077721, PubMed 15192310
9. Hjortland GO, Garman-Vik SS, Juell S, Olsen OE, Hirschberg H, Fodstad O, Engebraaten O (2004)
   Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme
   J Neurosurg, 100 (2), 320-7
   DOI 10.3171/jns.2004.100.2.0320, PubMed 15086240
10. Hjortland GO, Lillehammer T, Somme S, Wang J, Halvorsen T, Juell S, Hirschberg H, Fodstad Ø, Engebraaten O (2004)
    Plasminogen activator inhibitor-1 increases the expression of VEGF in human glioma cells
    Exp Cell Res, 294 (1), 130-9
    DOI 10.1016/j.yexcr.2003.10.013, PubMed 14980508
11. Jiang WG, Watkins G, Fodstad O, Douglas-Jones A, Mokbel K, Mansel RE (2004)
    Differential expression of the CCN family members Cyr61, CTGF and Nov in human breast cancer
    Endocr Relat Cancer, 11 (4), 781-91
    DOI 10.1677/erc.1.00825, PubMed 15613452
12. King JA, Ofori-Acquah SF, Stevens T, Al-Mehdi AB, Fodstad O, Jiang WG (2004)
    Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator
    Breast Cancer Res, 6 (5), R478-87
    DOI 10.1186/bcr815, PubMed 15318930
13. Pedersen KB, Andersen K, Fodstad Ø, Maelandsmo GM (2004)
    Sensitization of interferon-gamma induced apoptosis in human osteosarcoma cells by extracellular S100A4
    BMC Cancer, 4, 52
    DOI 10.1186/1471-2407-4-52, PubMed 15318945
14. Rappa G, Kunke D, Holter J, Diep DB, Meyer J, Baum C, Fodstad O, Krauss S, Lorico A (2004)
    Efficient expansion and gene transduction of mouse neural stem/progenitor cells on recombinant fibronectin
    Neuroscience, 124 (4), 823-30
    DOI 10.1016/j.neuroscience.2003.11.030, PubMed 15026123
15. Ree AH, Bratland A, Nome RV, Stokke T, Fodstad O, Andersson Y (2004)
    Inhibitory targeting of checkpoint kinase signaling overrides radiation-induced cell cycle gene regulation: a therapeutic strategy in tumor cell radiosensitization?
    Radiother Oncol, 72 (3), 305-10
    DOI 10.1016/j.radonc.2004.07.002, PubMed 15450729
16. Ree AH, Bratland A, Solberg Landsverk K, Fodstad O (2004)
    Ionizing radiation inhibits the PLK cell cycle gene in a G2 checkpoint-dependent manner
    Anticancer Res, 24 (2B), 555-62
    PubMed 15160994
17. Wang X, Wang M, Amarzguioui M, Liu F, Fodstad Ø, Prydz H (2004)
    Downregulation of tissue factor by RNA interference in human melanoma LOX-L cells reduces pulmonary metastasis in nude mice
    Int J Cancer, 112 (6), 994-1002
    DOI 10.1002/ijc.20527, PubMed 15386437